Good
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with the provided label excerpts (myelosuppression and malignancies), but many additional symptom, mechanism, indication, and specific-population/counseling claims are not supported by the provided excerpts, which limits on-label alignment assessment.
Category Scores
Accurate Statements
Hydroxyurea can decrease white blood cell counts (leukopenia).
Supported by excerpt 5.1: leukopenia is the first and most common manifestation of myelosuppression.
Hydroxyurea can decrease red blood cell counts (anemia).
Supported by excerpt 5.1: thrombocytopenia and anemia occur less often and are seldom seen without preceding leukopenia.
Hydroxyurea can decrease platelet counts (thrombocytopenia).
Supported by excerpt 5.1: thrombocytopenia occurs less often and is seldom seen without preceding leukopenia.
Hydroxyurea can increase the risk of infection.
Partially supported: the provided excerpts describe severe myelosuppression and monitoring for infection/bleeding signs in patient counseling (section 17), but do not explicitly tie infection risk to specific labeled wording beyond patient counseling; still consistent with 'signs and symptoms of infection' counsel.
Hydroxyurea can increase the risk of bleeding.
Partially supported: section 17 advises caregivers to report signs/symptoms of bleeding; the provided excerpts do not explicitly define 'bleeding risk' beyond that counseling.
Long-term use of hydroxyurea can increase the risk of developing secondary malignancies.
Supported by 5.3: hydroxyurea is a human carcinogen; secondary leukemia and skin cancer reported; advise long-term follow-up and monitoring for secondary malignancies.
All patients using XROMI should be followed up on a long-term basis with regular blood counts to detect development of leukemia.
Supported by 5.3.
Unsupported Statements
Hydroxyurea 500 mg can cause nausea.
Not supported by provided excerpts (no GI adverse event statements in 5.1/5.3/2.1/17).
Hydroxyurea 500 mg can cause vomiting.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause diarrhea.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause mouth sores.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause rash.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause hair loss.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause changes in skin color.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause headache.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause dizziness.
Not supported by provided excerpts.
Hydroxyurea 500 mg can cause fatigue.
Not supported by provided excerpts.
Hydroxyurea is used to manage chronic myeloid leukemia.
Provided excerpts discuss risks (myelosuppression/malignancies) and do not state indications.
Hydroxyurea is used to manage head and neck cancer.
Provided excerpts do not state this indication.
Hydroxyurea is a primary treatment for sickle cell anemia.
Provided excerpts mention sickle cell anemia in the context of secondary leukemia reporting, but do not provide indications or 'primary treatment' wording.
Hydroxyurea works by increasing fetal hemoglobin levels.
Provided excerpts do not describe mechanism.
In sickle cell anemia, hydroxyurea reduces the frequency of painful crises.
Provided excerpts do not describe efficacy outcomes.
In sickle cell anemia, hydroxyurea reduces the need for blood transfusions.
Provided excerpts do not describe efficacy outcomes.
Hydroxyurea is an antineoplastic agent.
Provided excerpts do not define pharmacologic class.
Hydroxyurea is a cytotoxic S-phase specific antimetabolite.
Provided excerpts do not describe mechanism/class.
Hydroxyurea inhibits DNA synthesis.
Provided excerpts do not describe mechanism.
Hydroxyurea slows down the proliferation of rapidly dividing cells by interfering with DNA replication.
Provided excerpts do not describe mechanism.
Hydroxyurea 500 mg can cause mouth sores.
Not supported by provided excerpts.
Hydroxyurea requires regular blood counts to detect anemia, leukopenia, and thrombocytopenia.
Partially supported by monitoring language (CBC/reticulocyte every 2 weeks during dose-escalation; then every 4 weeks once stable), but the claim is framed as 'requires' and specifically 'to detect anemia, leukopenia, and thrombocytopenia'—the excerpt specifies CBC/reticulocyte and myelosuppression manifestations; however the excerpt does not explicitly state detection rationale for each named cytopenia. Under strict excerpt-only evaluation, this is not fully supported as phrased.
Patients taking hydroxyurea should report signs of infection such as fever or sore throat.
Section 17 supports advising caregivers to report signs/symptoms of infection, but the specific examples 'fever or sore throat' are not provided in the excerpt.
Patients taking hydroxyurea should report unusual bleeding or bruising.
Section 17 supports advising caregivers to report signs/symptoms of bleeding, but 'bruising' wording is not provided in the excerpt.
Hydroxyurea is teratogenic.
Pregnancy/teratogenicity content is not present in the provided excerpts.
Hydroxyurea should be avoided during pregnancy.
Pregnancy guidance is not present in the provided excerpts.
Both men and women should use effective contraception during hydroxyurea treatment and for a period after the last dose.
Contraception guidance is not present in the provided excerpts.
Breastfeeding is not recommended while taking hydroxyurea.
Breastfeeding guidance is not present in the provided excerpts.
Hydroxyurea may pass into breast milk.
Breast milk content is not present in the provided excerpts.
Long-term hydroxyurea use can cause chronic skin changes or other persistent side effects.
Section 5.3 mentions skin cancer and cutaneous vasculitic toxicities broadly via counseling reference, but the excerpt provided does not support 'chronic skin changes or other persistent side effects' as a specific claim.
Contradictions
Important Omissions
Dose and administration details beyond monitoring (e.g., initial dose 15 mg/kg/day once daily, rounding rules, dose escalation/discontinuation based on blood counts) were not provided in the AI response; only partial monitoring-related content appears.
Importance:
Moderate
Label-required specifics for monitoring cadence: evaluate CBC and reticulocyte count prior to and every 2 weeks during dose-escalation, then every 4 weeks once stable dose achieved.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some on-label safety elements (myelosuppression manifestations, need for CBC/monitoring, infection/bleeding sign reporting, and long-term malignancy risk) are captured, but numerous other claims are unsupported by the provided excerpts, reducing confidence that the overall response accurately reflects on-label counseling/warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many statements (indications, mechanism, numerous adverse events, and pregnancy/breastfeeding/counseling specifics) are not supported by the provided FDA label excerpts, while only myelosuppression/leukopenia/anemia/thrombocytopenia and malignancy-related warnings are supported.
Suggested Improvement
Restrict claims to what is supported in the provided excerpts (5.1 myelosuppression; 5.3 carcinogenicity/secondary leukemia/skin cancer and long-term follow-up; 2.1 monitoring cadence and dose adjustment principles; 17 counseling to report infection/bleeding signs and use sun protection for secondary malignancy/skin cancer concerns). Avoid unsupported symptom examples, indication/mechanism/efficacy, and pregnancy/breastfeeding details absent from the supplied text.